Atossa Genetics (NASDAQ:ATOS) Announces Earnings Results

Atossa Genetics (NASDAQ:ATOS) announced its quarterly earnings results on Friday. The company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.07, FiscalAI reports.

Atossa Genetics Stock Down 2.5%

NASDAQ ATOS opened at $2.36 on Friday. Atossa Genetics has a fifty-two week low of $1.70 and a fifty-two week high of $19.35. The business has a 50 day moving average price of $2.62 and a two-hundred day moving average price of $4.51. The stock has a market cap of $20.32 million, a PE ratio of -0.74 and a beta of 1.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATOS. Ameriprise Financial Inc. bought a new position in Atossa Genetics during the 2nd quarter valued at $2,468,000. Renaissance Technologies LLC grew its stake in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after purchasing an additional 514,175 shares in the last quarter. Jane Street Group LLC acquired a new position in Atossa Genetics in the second quarter worth about $381,000. Qube Research & Technologies Ltd increased its holdings in Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after buying an additional 325,340 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Atossa Genetics by 4.2% during the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after buying an additional 245,717 shares in the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ATOS shares. Weiss Ratings cut Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Rodman & Renshaw began coverage on shares of Atossa Genetics in a report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.